Edwin Klumper joins from SMS-oncology

Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases by using its patented CriPec platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. He will be responsible for the clinical strategy and development of Cristal Therapeutics' range of nanomedicines.

As consultant and medical director Edwin has supervised over 80 oncology drug development programs and 20 clinical trials. Before joining Cristal Therapeutics, he served as interim-CEO of Dutch SMS-oncology, which he co-founded in 2007. He acted as CMO since the inception of the company until 2013. Prior to SMS-oncology, he served at Nabi Biopharmaceuticals as Vice-President Marketing & Sales Europe, at Amgen as Business Unit Director for The Netherlands, for the UK and as Brand Director Europe, at ASTA Medica as Product Manager, and at start-up Yew Tree Pharmaceuticals as Medical Director. He obtained his PhD as cancer research scientist at VU Academic Medical Center in Amsterdam, the Netherlands.